Clement MedLife Solutions Pvt. Ltd. is advancing a clinically driven poly-herbal formulation designed to support patients with persistently elevated
serum creatinine and early renal
function impairment.
Positioned at the intersection of traditional science and modern clinical validation, this program aims to address a critical gap in early-stage
kidney care.
Renal decline is often silent and progressive.
A large proportion of patients ultimately transition toward:
- Long-term dialysis
- Kidney transplantation
- Significant reduction in quality of life
Current standards of care primarily focus on slowing progression
There is a clear global need for early, safe, and scalable interventions.
Our Vision
To shift kidney care from late-stage management to early-stage intervention
This program is being developed with the long-term goal to:
- Preserve renal function at earlier stages
- Reduce progression toward dialysis dependency
- Lower future transplant burden globally
- Standardized capsule-based formulation
- Randomized controlled clinical validation (India)
- Alignment with global regulatory pathways (IND strategy)
- Alignment with global regulatory pathways (IND strategy)
- Integration with international CRO and commercialization partners
- Scalable global development model (US, EU, ROW)
Scientific & Strategic Foundation
- Evidence-driven formulation development
- Structured clinical protocol and endpoints
- Focus on measurable renal biomarkers
- Parallel advancement toward global regulatory submission
Our Commitment
Clement MedLife Solutions Pvt. Ltd. is committed to building a globally credible, clinically validated kidney care platform.
We combine:
- Traditional therapeutic knowledge
- Modern clinical research methodology
- Regulatory discipline
- Scalable global execution
The Mission
To deliver a clinically validated, accessible, and scalable solution for early kidney
function support—improving outcomes for patients worldwide.
Partner With Us
We are actively engaging with:
- Clinical research organizations (CROs)
- Regulatory and development partners
- Strategic investors
- Global commercialization leaders